Abstract
A total of 192 patients with benign fibrocystic disease of the breast were studied. Diagnosis was based on the clinical picture, xerography, and/or mammography. Most of the patients were 30-45 years old. Hormonal studies including serum PRL, 17-β-estradiol, progesterone, and gonadotropins were performed by means of specific and sensitive RIA techniques. Patients were allotted to treatment with 3 x 2.5 mg p.o. 2-bromo-α-ergocryptine (CB 154, Parlodel, Sandoz) continuously for a period of 3 months. In an attempt to establish a possible relationship between PRL levels and the disease, patients were divided into two groups with high or normal levels of PRL. Results indicate an improvement or complete recovery in about 75% of the cases. These results are independent of PRL levels. According to the authors' experience CB 154 seems to be the most effective treatment of this disease.
| Original language | English |
|---|---|
| Pages (from-to) | 479-481 |
| Number of pages | 3 |
| Journal | International Journal of Clinical Pharmacology Therapy and Toxicology |
| Volume | 20 |
| Issue number | 10 |
| Publication status | Published - 1982 |
Fingerprint
ASJC Scopus subject areas
- Toxicology
- Pharmacology (medical)
Cite this
Treatment of benign fibrocystic disease of the breast with 2-bromo-α-ergocryptine (CB 154). / Santoro, C.; Cappa, M.; Moretti, C.; Fabbri, A.; La Vecchia, V.; Romano Marcellino, L.; Fraioli, F.
In: International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 20, No. 10, 1982, p. 479-481.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of benign fibrocystic disease of the breast with 2-bromo-α-ergocryptine (CB 154)
AU - Santoro, C.
AU - Cappa, M.
AU - Moretti, C.
AU - Fabbri, A.
AU - La Vecchia, V.
AU - Romano Marcellino, L.
AU - Fraioli, F.
PY - 1982
Y1 - 1982
N2 - A total of 192 patients with benign fibrocystic disease of the breast were studied. Diagnosis was based on the clinical picture, xerography, and/or mammography. Most of the patients were 30-45 years old. Hormonal studies including serum PRL, 17-β-estradiol, progesterone, and gonadotropins were performed by means of specific and sensitive RIA techniques. Patients were allotted to treatment with 3 x 2.5 mg p.o. 2-bromo-α-ergocryptine (CB 154, Parlodel, Sandoz) continuously for a period of 3 months. In an attempt to establish a possible relationship between PRL levels and the disease, patients were divided into two groups with high or normal levels of PRL. Results indicate an improvement or complete recovery in about 75% of the cases. These results are independent of PRL levels. According to the authors' experience CB 154 seems to be the most effective treatment of this disease.
AB - A total of 192 patients with benign fibrocystic disease of the breast were studied. Diagnosis was based on the clinical picture, xerography, and/or mammography. Most of the patients were 30-45 years old. Hormonal studies including serum PRL, 17-β-estradiol, progesterone, and gonadotropins were performed by means of specific and sensitive RIA techniques. Patients were allotted to treatment with 3 x 2.5 mg p.o. 2-bromo-α-ergocryptine (CB 154, Parlodel, Sandoz) continuously for a period of 3 months. In an attempt to establish a possible relationship between PRL levels and the disease, patients were divided into two groups with high or normal levels of PRL. Results indicate an improvement or complete recovery in about 75% of the cases. These results are independent of PRL levels. According to the authors' experience CB 154 seems to be the most effective treatment of this disease.
UR - http://www.scopus.com/inward/record.url?scp=0019981741&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019981741&partnerID=8YFLogxK
M3 - Article
C2 - 6815107
AN - SCOPUS:0019981741
VL - 20
SP - 479
EP - 481
JO - International Journal of Clinical Pharmacology and Therapeutics
JF - International Journal of Clinical Pharmacology and Therapeutics
SN - 0174-4879
IS - 10
ER -